Compare Docusign Inc (DOCU) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs Neurocrine Biosciences Inc — how do they compare? Docusign Inc trades at $49.41 (market cap $9.43B), while Neurocrine Biosciences Inc trades at $170.05 (market cap $17.30B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Docusign Inc nearer its low. Which is the better fit depends on your goals.
| DOCU | NBIX | |
|---|---|---|
Market Cap | $9.43B | $17.30B |
Sector | Technology | Health |
52-Week High | $85.01 | $180.55 |
52-Week Low | $41.75 | $123.10 |
Enterprise Value | $8.80B | $16.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $49.87, up 1.4% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals with revenue growth to $2.98B in 2025 and net income of $1.07B, supported by consistent earnings beats. Recent partnerships with Perplexity and Slack highlight innovation in agreement management, while analyst sentiment remains mixed with a $55.40 consensus target.
Outlook is cautiously optimistic given solid profitability and strategic initiatives, but risks include pricing pressure and sector volatility. The stock presents a growth opportunity if execution continues, though investor patience is required amid competitive and macroeconomic headwinds.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
